Overlooking the obvious? On the potential of treatment alterations to predict patient-specific therapy response

被引:2
|
作者
Roeder, Ingo [1 ,2 ]
Glauche, Ingmar [1 ]
机构
[1] Tech Univ Dresden, Inst Med Informat & Biometry, Carl Gustav Carus Fac Med, Fetscherstr 74, D-01307 Dresden, Germany
[2] Natl Ctr Tumor Dis NCT, Core Unit Data Management & Analyt, Partner Site Dresden, Dresden, Germany
关键词
D O I
10.1016/j.exphem.2020.11.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prognostic or therapeutic classification of diseases is often based on clinical or genetic characteristics at diagnosis or response landmarks determined at a certain time point of treatment. On the other hand, there are more and more means, such as molecular markers and sensor data, that allow for quantification of disease or therapeutic parameters over time. Although a general value of time-resolved disease monitoring is widely accepted, the full potential of using the available information on disease and treatment dynamics in the context of outcome prediction or individualized treatment optimization still seems to be, at least partially, overlooked. Within this Perspective, we summarize the conceptual idea of using dynamic information to obtain a better understanding of complex pathophysiological processes within their particular "host environment," which also allows us to intrinsically map patient-specific heterogeneity. Specifically, we discuss to which extent treatment alterations can provide additional information to understand a patient's individual condition and use this information to further adapt the therapeutic strategy. This conceptual discussion is illustrated by using examples from myeloid leukemias to which we recently applied this concept using statistical and mathematical modeling. (c) 2020 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:26 / 30
页数:5
相关论文
共 50 条
  • [11] Breast Cancer Organoids Model Patient-Specific Response to Drug Treatment
    Campaner, Elena
    Zannini, Alessandro
    Santorsola, Mariangela
    Bonazza, Deborah
    Bottin, Cristina
    Cancila, Valeria
    Tripodo, Claudio
    Bortul, Marina
    Zanconati, Fabrizio
    Schoeftner, Stefan
    Del Sal, Giannino
    CANCERS, 2020, 12 (12) : 1 - 19
  • [12] Patient-specific HLA-I genotypes predict response to immune checkpoint blockade
    Shohdy, K. S.
    Atherton, J.
    Longland, J.
    Allison, J. L. E.
    Pillai, M.
    Thistlethwaite, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S255 - S255
  • [13] A Novel Method of Using Molecular Profiling in Myelodysplastic Syndromes to Predict Patient-Specific Potential Therapeutics
    Cogle, Christopher R.
    Trikha, Gaurav
    Sayeski, Peter P.
    Vali, Shireen
    Kumar, Ansu
    Singh, Neeraj Kumar
    Nair, Prashant R.
    Lala, Deepak Anil
    Basu, Kabya
    Abbasi, Taher
    Albitar, Maher
    BLOOD, 2014, 124 (21)
  • [14] A method to predict patient-specific table coordinates for quality assurance in external beam radiation therapy
    Saenz, Daniel L.
    Astorga, Nestor Rodrigo
    Kirby, Neil
    Fakhreddine, Mohamad
    Rasmussen, Karl
    Stathakis, Sotirios
    Papanikolaou, Niko
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2018, 19 (05): : 625 - 631
  • [16] The case for patient-specific dosimetry in radionuclide therapy
    Stabin, Michael G.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (03) : 273 - 284
  • [17] Toward Patient-Specific, Biologically Optimized Radiation Therapy Plans for the Treatment of Glioblastoma
    Corwin, David
    Holdsworth, Clay
    Rockne, Russell C.
    Trister, Andrew D.
    Mrugala, Maciej M.
    Rockhill, Jason K.
    Stewart, Robert D.
    Phillips, Mark
    Swanson, Kristin R.
    PLOS ONE, 2013, 8 (11):
  • [18] 3D tissue models to predict patient-specific response to immunooncology based therapies
    Appleton, Kathryn M.
    Lotstein, Alina
    Guo, Qi
    Elrod, Ashley
    Puls, Larry
    Elder, Jeffrey
    Holmes, Lillia
    Crosswell, Howland E.
    DesRochers, Teresa M.
    CANCER RESEARCH, 2018, 78 (13)
  • [19] Patient-specific motion and treatment margins in pancreatic stereotactic body radiation therapy
    Miften, M.
    Jones, B. L.
    Fukami, N.
    Schefter, T.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S198 - S199
  • [20] Options for radionuclide therapy: From fixed activity to patient-specific treatment planning
    Thomas, SR
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2002, 17 (01) : 71 - 82